Raymond James Financial
KYTX icon

Raymond James Financial’s Kyverna Therapeutics KYTX Stock Holding History

Raymond James Financial’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,082
Closed -$139K – 5602
2026
Q1 		$139K Sell
16,082
-9,000
-36% -$75K ﹤0.01% 4964
2025
Q4 		$236K Buy
+25,082
New +$186K ﹤0.01% 4709
2025
Q3 		– Sell
-189
Closed -$580 – 6854
2025
Q2 		$580 Buy
+189
New +$467 ﹤0.01% 6656

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Raymond James Financial's KYTX Position: Q2 2026 in Review

Raymond James Financial sold out of Kyverna Therapeutics (KYTX) in Q2 2026, closing a stake of 16,082 shares — an estimated $139K sold.

Raymond James Financial first reported a position in KYTX in Q2 2025 and held it in 3 quarters. The position peaked at $236K in Q4 2025. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Raymond James Financial reported no remaining Kyverna Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Raymond James Financial sold 16,082 Kyverna Therapeutics shares in Q2 2026, an estimated $139K.
  • Raymond James Financial first reported a position in Kyverna Therapeutics in Q2 2025 and held it in 3 quarters.
  • Raymond James Financial's Kyverna Therapeutics position peaked at $236K in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.